Hence, an ICI is a monoclonal antibody that targets a specific immune checkpoint, in which PD-1 is highly expressed on T, NK, and myeloid immune cells while PD-L1 is found either on tumor or activated macrophages, T cells, and CAFs [1,44]. Here, PDCD1 is linked to neoplasm.